A wonderful boy, Ivan Bokov, is being treated in the Department of Immunology of the Federal Clinical Research Center. He is suffering from juvenile rheumatoid arthritis. The boy vitally needs the Canakinumab drug, which is currently unavailable in the FCRC. Breaks in taking the drug are not allowed.
Ivan is 6 years old now. The disease started when he was 3 years and 10 months. A sudden fever broke out, which doctors failed to subdue. The boy was coming in rash, his liver and spleen were substantially enlarged. The kid was taken to an infectious diseases hospital, where he received treatment with antibiotics, not bringing any results though. On November 1, 2010, he was transferred to a regional hospital, where he was diagnosed with juvenile rheumatoid arthritis (systemic onset). Due to a serious condition, on December 5, 2010, the boy was transferred to Children's Department of the Institute of Rheumatology in Moscow. The child developed bilateral cataract, his growth stopped, substantial changes in internals and joints have occurred. In February, 2013, Ivan’s condition worsened again, and a therapy with Canakinumab was administered by the physicians of the FCRC. The positive effect from taking the drug was obvious even after the first its administration.
Ivan is a very smart boy and dreams of staying with his peers, going to kindergarten, and simply playing in the company of other children, however his illness does not yet allow him to do that. Canakinumab is the only hope now. The problem is, parents can’t afford buying the drug.